The Global University Venturing deal net rounds up the smaller investments from across the university innovation ecosystem.

Celsius, a US-based cancer and autoimmune disease drug developer, has pocketed $83m in a funding round led by Casdin Capital and backed by founding investor Third Rock Ventures. The round included technology group Alphabet’s GV unit, medical care provider Heritage Provider Network and pharmaceutical firm Amgen’s corporate venturing arm Amgen Ventures. Life sciences-focused real estate…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Talking Tech Transfer interview podcast and responsible for the monthly GUV Gazette (sign up here for free).